1. National Institute of Mental Health . Schizophrenia. www.nimh.nih.gov/health/topics/schizophrenia/index.shtml (2020, accessed 15 July 2021).
Google Scholar2. Andreasen, NC. Scale for the assessment of positive symptoms (SAPS). Rating scale. University of Iowa, IA: Department of Psychiatry, College of Medicine University of Iowa, 1984.
Google Scholar3. D’Arrigo, T. Schizophrenia symptoms. WebMD, www.webmd.com/schizophrenia/schizophrenia-symptoms (2020, accessed 15 July 2021).
Google Scholar4. Andreasen, NC. Scale for the assessment of negative symptoms (SANS). Rating scale. University of Iowa, IA: Department of Psychiatry, College of Medicine University of Iowa, 1984.
Google Scholar5. Vyas, P, Hwang, BJ, Brašić, JR. An evaluation of lumateperone tosylate for the treatment of schizophrenia. Expert Opin Pharmacother 2020; 21: 139–145.
Google Scholar | Crossref | Medline6. Haddad, PM, Correll, CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol 2018; 8: 303–318.
Google Scholar | SAGE Journals | ISI7. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1211–1259.
Google Scholar | Crossref | Medline8. McGrath, J, Saha, S, Chant, D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008; 30: 67–76.
Google Scholar | Crossref | Medline | ISI9. Abel, KM, Drake, R, Goldstein, JM. Sex differences in schizophrenia. Int Rev Psychiatry 2010; 22: 417–428.
Google Scholar | Crossref | Medline | ISI10. Brašić, JR. Neurotransmitter visualization in schizophrenia. J Biomed Graph Comput 2013; 3: 30–45.
Google Scholar11. Toda, M, Abi-Dargham, A. Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep 2007; 9: 329–336.
Google Scholar | Crossref | Medline12. Wong, DF, Brašić, JR. Progress in the neuropsychiatry of schizophrenia. Psychiatr Times 2005; 22: 57, 58, 60.
Google Scholar13. Wong, DF, Gründer, G, Cascella, NG, et al. Molecular brain imaging in schizophrenia. In: Sadock, BJ, Sadock, VA, Ruiz, P (eds) Kaplan & Sadock’s comprehensive textbook of psychiatry. 9th ed. Philadelphia: Lippincott Williams & Wilkins, 2009, pp.1519–1530.
Google Scholar14. Wong, DF, Brašić, JR, Cascella, N. Neuroreceptor imaging of schizophrenia. In: Shenton, ME, Turetsky, BI (eds). Understanding neuropsychiatric disorders: insights from neuroimaging. Cambridge: Cambridge University Press, 2011, pp.78–87.
Google Scholar15. Wong, DF, Brašić, JR, Horti, A, et al. Molecular brain imaging in schizophrenia. In: Sadock, BJ, Sadock, VA, Ruiz, P (eds) Kaplan & Sadock’s comprehensive textbook of psychiatry. 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2017, pp.1488–1501.
Google Scholar16. Musco, S, McAllister, V, Caudle, I. Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment. Ther Adv Psychopharmacol 2020; 10: 2045125320937575.
Google Scholar | SAGE Journals17. Marder, SR, Davis, MC. First-generation antipsychotics. In: Sadock, BJ, Sadock, VA, Ruiz, P (eds) Kaplan & Sadock’s comprehensive textbook of psychiatry. 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2017, pp.3170–3218.
Google Scholar18. Lieberman, JA, Davis, RE, Correll, CU, et al. ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry 2016; 79: 952–961.
Google Scholar | Crossref | Medline19. Meltzer, HY, Gadeleta, E. Contrasting typical and atypical antipsychotic drugs. Focus 2021; 19: 3–13.
Google Scholar | Crossref20. Strassnig, MT, Harvey, PD. Second-generation antipsychotics. In: Sadock, BJ, Sadock, VA, Ruiz, P (eds) Kaplan & Sadock’s comprehensive textbook of psychiatry. 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2017, pp.3059–3082.
Google Scholar21. Davis, RE, Vanover, KE, Zhou, Y, et al. ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers. Psychopharmacology 2015; 232: 2863–2872.
Google Scholar | Crossref | Medline22. Citrome, L. Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next? CNS Spectr 2016; 21(Suppl. 1): 4–11.
Google Scholar | Crossref23. Hultcrantz, M, Rind, D, Akl, EA, et al. The GRADE Working Group clarifies the construct of certainty of evidence. J Clin Epidemiol 2017; 87: 4–13.
Google Scholar | Crossref | Medline24. Blair, HA. Lumateperone: first approval. Drugs 2020; 80: 417–423.
Google Scholar | Crossref | Medline25. Cooper, D., Lumateperone. Lumateperone. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing, 2021.
Google Scholar26. Lumateperone (Caplyta) for schizophrenia . Med Lett Drugs Ther 2020; 62: 113–116.
Google Scholar | Medline27. Edinoff, A, Wu, N, deBoisblanc, C, et al. Lumateperone for the treatment of schizophrenia. Psycholpharmacol Bull 2020; 50: 32–59.
Google Scholar28. Frampton, JE. Lumateperone in schizophrenia: a profile of its use. Drugs Ther Perspect 2020; 36: 477–484.
Google Scholar | Crossref29. Greenwood, J, Acharya, RB, Marcellus, V, et al. Lumateperone: a novel antipsychotic for schizophrenia. Ann Pharmacother 2021; 55: 98–104.
Google Scholar | SAGE Journals | ISI30. Kumar, B, Kuhad, A, Kuhad, A. Lumateperone: a new treatment approach for neuropsychiatric disorders. Drugs Today 2018; 54: 713–719.
Google Scholar | Crossref | Medline31. Mazza, M, Marano, G, Traversi, G, et al. Evidence on the new drug lumateperone (ITI-007) for psychiatric and neurological disorders. CNS Neurol Disord Drug Targets 2020; 19: 243–247.
Google Scholar | Crossref | Medline32. Davis, JM. Commentary on: Corponi, F., Fabbri, C, Bitter, I., Montgomery, S., Vieta, E., Kaspar, S., Pallanti, S., Serretti, A. Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol 2019; 29: 1061–1062.
Google Scholar | Crossref | Medline33. Limandri, BJ. Lumateperone: new drug or same old drug with a new dress? J Psychosoc Nurs Ment Health Serv 2020; 48: 9–12.
Google Scholar34. Higgins, JPT, Green, S (eds) Cochrane handbook for systematic reviews of interventions. Chicester: John Wiley & Sons Ltd, 2008.
Google Scholar | Crossref35. Reddy, HM, Poole, JS, Maguire, GA, et al. New medications for neuropsychiatric disorders. Psychiatr Clin N Am 2020; 43: 399–413.
Google Scholar | Crossref | Medline36. Davis, RE, Correll, CU. ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. Expert Rev Neurother 2016; 16: 601–614.
Google Scholar | Crossref | Medline37. Dimitrelis, K, Shankar, R. Pharmacological treatment of schizophrenia – a review of progress. Prog Neurol Psychiatry 2016; 20: 28–35.
Google Scholar | Crossref38. Li, P, Zhang, Q, Robichaud, AJ, et al. Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. J Med Chem 2014; 57: 2670–2682.
Google Scholar | Crossref | Medline39. Snyder, GL, Vanover, KE, Davis, RE, et al. A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia. Adv Pharmacol 2021; 90: 253–276.
Google Scholar | Crossref | Medline40. Snyder, GL, Vanover, KE, Zhu, H, et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology 2015; 232: 605–621.
Google Scholar | Crossref | Medline41. Guillin, O. Les antipsychotiques de la future decade. [What antipsychotic drugs will be in the next decade.] Bull Acad Natl Med 2020; 204: 1043–1046.
Google Scholar | Medline42. Center for Drug Evaluation and Research . Approval package for: application number: 209500Orig1s000 2019. Silver Spring, MD: Food and Drug Administration, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209500Orig1s000Approv.pdf (2019, accessed 15 July 2021).
Google Scholar43. Intra-Cellular Therapies Inc . Caplyta (lumateperone) capsules, for oral use (package insert). New York: Intra-Cellular Therapies, Inc. https://www.intracellulartherapies.com/docs/caplyta_pi.pdf (2019, accessed 15 July 2021).
Google Scholar44. Tomesch, J, Wennogle, L. 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals. Patent 9199995-B2, USA, 2015.
Google Scholar45. Vanover, K, Glass, S, Kozauer, S, et al. Lumateperone (ITI-007) for the treatment of schizophrenia: overview of placebo-controlled clinical trials and an open-label safety switching study [abstract no. 30]. CNS Spectr 2019; 24: 190–191. [abstract]
Google Scholar | Crossref46. Vanover, KE, Davis, RE, Zhou, Y, et al. Dopamine D2 receptor occupancy of lumateperone (ITI-007): a positron emission tomography study in patients with schizophrenia. Neuropsychopharmacology 2019; 44: 598–605.
Google Scholar | Crossref | Medline47. Vanover, K, Dmitrienko, A, Glass, A, et al. Lumateperone (ITI-007) for the treatment of schizophrenia: placebo-controlled clinical trials and an open-label safety switching study. Schizophr Bull 2019; 45(Suppl. 2): S341. [abstract]
Google Scholar48. Vanover, K, O’Gorman, C, Glass, S, et al. Favorable clinical safety profile for lumateperone (ITI-007) – switching from standard-of-care antipsychotic therapy in patients with schizophrenia [abstract no. T189]. Neuropsychopharmacology 2017; 42(Suppl. 1): S416–S417. [abstract]
Google Scholar49. Vanover, K, Satlin, A, Durgam, S, et al. Favorable long-term safety profile of lumateperone IITI-007): results from a 12 month open label safety study for lumateperone in patients with stable symptoms of schizophrenia. Schizophr Bull 2019; 45(Suppl. 2): S351. [abstract]
Google Scholar | Crossref50. Zhang, L, Hendrick, JP. The presynaptic D2 partial agonist lumateperone acts as a postsynaptic D2 antagonist. Matters 2018; 1–4.
Google Scholar51. Wang, S-M, Han, C, Lee, S-J, et al. Investigational dopamine antagonists for the treatment of schizophrenia. Expert Opin Investig Drugs 2017: 26: 687–698.
Google Scholar | Crossref | Medline52. Svensson, T, Dutheil, S, Hendrick, J, et al. Lumateperone uniquely enhances glutamatergic neurotransmission through activation of both NMDA and AMPA channels via a dopamine D1 receptor-dependent mechanism: implications for treatment of mood disorders. Neuropsychopharmacology 2017; 42(Suppl. 1): S160. [abstract]
Google Scholar53. Capuzzi, E, Caldiroli, A, Ciscato, V, et al. Experimental serotonergic agents for the treatment of schizophrenia. J Exp Pharmacol 2021; 13: 49–67.
Google Scholar | Crossref | Medline54. Titulaer, J, Radhe, O, Ström, A, et al. The actions of lumateperone and single nucleotide polymorphism (SNP) converge on the glutamate-NO-cGMP pathway. Eur Neuropsychopharmacol 2020; 40(Suppl. 1): S332. [abstract]
Google Scholar | Crossref55. Kantrowitz, JT. The potential role of lumateperone – something borrowed? Something new? JAMA Psychiatry 2020; 77: 343–344.
Google Scholar | Crossref | Medline56. Farah, A. High-dose lumateperone: a case report. Curr Psychiatr 2021; 20: 42.
Google Scholar57. Naguy, A, Alamiri, B. 2019 FDA approved psychotherapeutic medications. Asian J Psychiatr 2020; 49: 101976.
Google Scholar | Crossref | Medline58. Olasupo, SB, Uzairu, A, Shallangwa, GA, et al. Unveiling novel inhibitors of dopamine transporter via in silico drug design, molecular docking, and bioavailability predictions as potential antischizophrenic agents. Futur J Pharm Sci 2021; 7: 63.
Google Scholar | Crossref59. He, Y, McLeod, HL. Pharmacokinetics for the prescriber. Medicine 2016; 44: 407–411.
Google Scholar | Crossref60. Orsolini, L, De Berardis, D, Volpe, U. Up-to-date expert opinion on the safety of recently developed antipsychotics. Expert Open Drug Saf 2020; 19: 981–998.